The murine scavenger receptor class B, type I (mSR-BI) is a receptor for high density lipoprotein (HDL), low density lipoprotein (LDL), and acetylated LDL (AcLDL
Reverse cholesterol transport has been proposed to play an important role in the removal of the excess cholesterol from peripheral tissues to the liver for disposal (1, 2) . The first step in reverse cholesterol transport is the efflux of free cholesterol from peripheral tissues to extracellular lipoprotein acceptors. A standard approach for measuring cholesterol efflux has been labeling cultured cells with [ 3 H]cholesterol and then measuring transfer of the label into culture medium with or without a suitable acceptor (e.g. serum, purified lipoproteins, phospholipid vesicles, etc.) (3, 4) . The efflux efficiency of serum is closely associated with its ␣-lipoprotein content, and both HDL 1 and lipid-free apoA-I can function as acceptors in in vitro efflux assays (reviewed in Ref. 2) . In most of the studies using HDL and serum as acceptors, it is likely that the movement of cholesterol was bidirectional (into as well as out of the cells) (2) , even though only efflux of labeled cholesterol was measured. The molecular mechanisms underlying [ 3 
H]cholesterol efflux studied in cultured cell assays and cholesterol transport in vivo
have not yet been defined in detail, and their precise relationships remain to be demonstrated.
The mechanisms of lipid-free apoA-I-and HDL particle-mediated cholesterol efflux are not identical. Lipid-free apoA-Imediated cholesterol efflux is unidirectional, resulting in the net loss of cellular cholesterol and phospholipid (5) . Important insights into this mechanism have come from studies of Tangier disease. Subjects with homozygous Tangier disease exhibit an almost complete absence of plasma HDL and the accumulation of cholesteryl ester in many tissues (see reviews in Refs. 6 and 7). The in vitro binding of apoA-I (6) and apoA-I-mediated cholesterol efflux are severely impaired in fibroblasts from these patients. Recently, mutations in the ATP-binding cassette transporter-1 (ABC1) gene were shown to be responsible for Tangier disease (8 -11) . ABC1 knockout mice have been generated and shown to exhibit many of the phenotypes of Tangier patients (12, 13) . Cholesterol loading and treatment with cAMP (11, 12) induce expression of the ABC1 protein, an integral membrane protein found on the plasma membrane and Golgi complex. The mechanism of its involvement in cholesterol transport is currently under intense investigation.
The identification and characterization of the HDL receptor SR-BI (14, 15) raised the possibility that this receptor might also participate in cholesterol efflux (16, 17) . SR-BI, a member of the CD36 superfamily of proteins, plays a key role in HDL and cholesterol metabolism as a receptor mediating selective cholesterol uptake (influx) from HDL to cells (14) . Tall and co-workers (18) were the first to directly demonstrate that transfection-mediated overexpression of SR-BI in cultured cells increases the rate of [ 3 H]cholesterol efflux from the cell to HDL particles, but not to free apoA-I. This is consistent with recent studies that show that lipid-free apoA-I is a poor ligand for SR-BI (19) . There is also a correlation between the level of SR-BI expressed by a variety of cultured cells and the rate of [ 3 H]cholesterol efflux from those cells (18) . Importantly, SR-BI can increase the rate of [ 3 H]cholesterol efflux to reconstituted cholesterol-free HDL particles, suggesting that SR-BI can mediate net cholesterol efflux and could potentially contribute to net cholesterol efflux in some circumstances in vivo (18) . Unlike cholesterol efflux to lipid-free apoA-I, SR-BI-mediated transfer of cholesterol between HDL or other soluble carriers and cells is a bidirectional (exchange) process (20) . It is likely that the direction of net cholesterol movement in this process depends on the relative concentrations of cholesterol in the plasma membrane and the acceptor particles. SR-BI can also bind to LDL and mediates the bidirectional exchange of cholesterol between cells and LDL particles in vitro (20) .
The mechanism by which SR-BI promotes cellular cholesterol efflux to (or exchange with) lipoproteins has been the subject of several recent studies (21, 22) . de la Llera-Moya et al. (21) have shown that SR-BI does not mediate efficient cholesterol efflux to HDL by merely bringing the HDL particles close to the cell surface (docking or tethering). They showed that CD36, which was known to bind HDL (23, 24) , but cannot mediate efficient selective lipid uptake as does SR-BI (24, 25) (21) . Furthermore, they discovered that transfectionmediated SR-BI overexpression by COS cells can alter the "lipid organization" of the cells' plasma membranes, as measured by an assay of cellular cholesterol accessibility to the enzyme cholesterol oxidase added to the extracellular medium (21, 22) . The molecular changes underlying the SR-BI-dependent change in cholesterol accessibility to the oxidase have not yet been defined. Based on these and other findings, Rothblat et al. (2, 21) proposed that SR-BI may not have to bind directly to an acceptor in cell culture medium to mediate enhanced [ 3 H]cholesterol efflux from SR-BI-expressing cells to that acceptor. They suggested that this proposed binding-independent SR-BI-mediated efflux might be a consequence of the altered cell-surface lipid organization (2, 21) .
The generation in our laboratories of two reagents for the analysis of the structure and function of SR-BI has provided an opportunity to further explore the mechanism of SR-BI-mediated [ 3 H]cholesterol efflux. The first of these reagents, which follows from the earlier work of Temel et al. (27) , is a high titer, specific rabbit anti-murine SR-BI antiserum that blocks HDL binding and lipid uptake (see below). The second is a set of SR-BI mutants that exhibit altered ligand binding properties, e.g. loss of ability to bind HDL, but not LDL (Ref. 28 and see below). The cDNAs encoding these mutants were isolated from a randomly mutated library of murine (m)SR-BI cDNAs using the retrovirus library-based activity dissection method (28) . One of these mutants has a double substitution of arginines for glutamines at positions 402 and 418 (Q402R/Q418R). This mutant SR-BI is as effective as wild-type mSR-BI in functioning as an LDL receptor, mediating high affinity LDL binding and uptake of metabolically active cholesterol from LDL; but it has lost most of the corresponding HDL receptor activity exhibited by the wild-type receptor (28) . Another previously unreported mutant with a Met-to-Arg substitution at position 158 (M158R) has diminished HDL and LDL receptor activities, but apparently normal acetylated LDL (AcLDL) receptor activity. In this report, we examined the effects of the blocking antibody and the Q402R/Q418R and M158R mutations on SR-BI-mediated cellular [ 3 H]cholesterol efflux. We also tested the effect of the anti-SR-BI blocking antibody on the plasma membrane lipid organization (the size of the cholesterol oxidase-accessible cholesterol pool). The results strongly suggest that HDL and LDL binding to SR-BI is a prerequisite for SR-BI-mediated efflux of cholesterol to these lipoproteins. HDL, LDL, AcLDL,   125   I-HDL,   125 I-LDL, DiI-labeled HDL, DiI-labeled LDL, DiI-labeled AcLDL, and Alexa-labeled HDL were prepared as described previously (14, 24, 28, 29) . [1, [2] [3] H]Cholesterol (1 mCi/ml, specific activity of 40 -60 Ci/mmol) was from NEN Life Science Products. Cholesterol oxidase (Streptomyces sp.), cholesterol, 4-cholesten-3-one, and cholesterol oleate were from Sigma. Silica Gel 60 TLC plates were from Fisher. The GenePORTER transfection reagent was from GTS Inc. All other reagents were obtained from standard commercial sources or as described previously (30) .
EXPERIMENTAL PROCEDURES

Materials-Human
Cell (14, 24, 28, 29) . The ldlA-7, ldlA[mSR-BI], and ldlA[Q402R/Q418R] cells were described previously (14, 28, 31) . To generate ldlA[M158R] cells, ldlA-7 cells grown in 100-mm dishes were cotransfected with 10 g of pcM158R plasmid (see below) and 1 g of pBK-CMV plasmid (Stratagene) using the GenePORTER transfection reagent according to the manufacturer's instructions. Stably transfected cells were selected in Ham's F-12 medium containing 50 units/ml penicillin, 50 g/ml streptomycin, and 2 mM glutamine (medium A) supplemented with 5% FBS (medium B) and 500 g/ml G418 for 2 weeks. They were then labeled with anti-mSR-BI KKB-1 antiserum (1:1000 dilution; see below) and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (1:1000 dilution; Cappel, West Chester, PA). Individual cells with high levels of M158R expression were isolated by fluorescence-activated cell sorting and cloned as described previously (28) . In addition, eight additional clones of ldlA-7 cells expressing the Q402R/Q418R mutant and one additional clone expressing wild-type mSR-BI were also isolated. For Isolation of KKB-1 Antibody-New Zealand White rabbits were immunized by intravenous injection of 10 13 particles of Ad.mSR-BI, a recombinant adenovirus encoding mSR-BI (17) . Serum was obtained 6 weeks post-injection or later, and IgG fractions were prepared using protein A-Sepharose column purification (Sigma). Control serum and associated IgG were obtained from a non-immunized New Zealand White rabbit. On day 2, cells were washed once with medium A and incubated for 45 min at 37°C with 0.5 ml of medium C (medium A containing 0.5% fatty acid-free bovine serum albumin) containing one of the following: no additions, nonimmune serum (1:1000 dilution), anti-mSR-BI KKB-1 serum (1:1000 dilution), nonimmune IgG (50 g/ml), or anti-mSR-BI KKB-1 IgG (50 g/ml). 55 l of medium C containing 500 g/ml either 125 I-HDL or 125 I-LDL were then added to each well (final lipoprotein concentration of 50 g of protein/ml). After incubation at 37°C for an additional 1.5 h, the cells were washed, and cell-associated I-LDL were measured as described previously (14, 24) . containing mSR-BI cDNA (pcDNA1-mSR-BI) using the GenePORTER transfection reagent. Briefly, cells were plated at 500,000 cells/dish in 100-mm dishes in medium D (Dulbecco's modified Eagle's medium containing 50 units/ml penicillin, 50 g/ml streptomycin, and 2 mM glutamine) supplemented with 10% FBS (medium E) on day 0. On day 1, cells were transfected with 10 g of the indicated plasmids according to the manufacturer's instruction. On day 2, cells were harvested with trypsin and replated in 24-well dishes at a cell density of 150,000 cells/well in medium E. After incubation at 37°C for 5 h, the medium was aspirated, replaced with 1 ml of labeling medium (medium D containing 10% heat-inactivated FBS and 1 Ci/ml [1,2- 3 H]cholesterol added in ethanol), and incubated at 37°C overnight. On day 3, the cells were washed twice with medium D, and 1 ml of equilibration medium 1 (medium D containing 1% fatty acid-free bovine serum albumin) was added to each well. On day 4, the cells were washed twice with medium D and incubated with 0.5 ml of medium D containing no additions, nonimmune serum (1:1000 dilution), or anti-mSR-BI KKB-1 serum (1:1000 dilution) for 45 min at 37°C. 55 l of medium D containing 2 mg of protein/ml HDL were then added to each well (final HDL concentration of 200 g of protein/ml). After a 2-h incubation at 37°C, the [ 3 H]cholesterol contents of the cells and the media were determined as follows. The efflux media were collected and clarified by centrifugation for 1 min with a desktop microcentrifuge, and the radioactivity in 100 l of each supernatant was determined by liquid scintillation counting (LSC). Cells were solubilized with 400 l of lysis buffer (1% Triton X-100 in PBS) for 30 min at room temperature, and the amount of 3 H]cholesterol, and equilibrated as described above. Cells were then incubated with 0.5 ml of medium D containing no additions, nonimmune serum, or anti-mSR-BI KKB-1 serum for 45 min at 37°C as described above for the efflux assay. 55 l of medium D containing 5 units/ml cholesterol oxidase were then added to each well (final cholesterol oxidase concentration of 0.5 units/ml). After incubation for 1 h at 37°C, the cells were washed once with medium D, and the lipids were extracted with hexane/isopropyl alcohol (3:2) and analyzed by thin-layer chromatography on Silica Gel 60 plates using hexane/methanol/ethyl ether (96:15:8) and cholesterol, 4-cholesten-3-one, and cholesterol oleate as internal standards (21 day 0, cells were plated in either 6-or 24-well plates as described above. On day 1, the medium in each well was replaced with 2 ml (6-well plates) or 1 ml (24-well dishes) of labeling medium (medium A containing 10% heat-inactivated NCLPDS (or FBS) and 1 Ci/ml [1,2- 3 H]cholesterol). On day 3, cells were washed once with medium A and then incubated in 2 ml (1 ml for 24-well dishes) of equilibration medium 2 (medium A containing 1% fatty acid-free bovine serum albumin). On day 4, cells were washed once with medium A. Cells were then incubated at 37°C for 45 min with 1 ml (0.5 ml for 24-well dishes) of medium A with or without anti-mSR-BI KKB-1 serum (1:1000 dilution). After a single washing with medium A, 1 ml (0.5 ml for 24-well dishes) of efflux medium (medium A containing 10 mM HEPES (pH 7.0) and the indicated amount of lipoproteins with or without antibody (1:1000 dilution)) was added to each well. Cells were then incubated at 37°C. At the indicated times, 120 l of efflux medium were removed from the wells and clarified by centrifugation for 1 min in a microcentrifuge. The radioactivity in 100 l of the supernatant was then measured by LSC. At the end of the incubation, the remaining efflux medium was discarded, and the cells were lysed in 800 l (400 l for 24-well dishes) of lysis buffer for 30 min at room temperature. The radioactivity in 100 l of each cell lysate was determined by LSC, and efflux (expressed as percent of total cellular [ 3 H]cholesterol) was calculated as described above for COS M6 cells. The use of this cell lysate method to quantify the levels of cell-associated [ 3 H]cholesterol was validated in several experiments by a direct comparison with the hexane/isopropyl alcohol extraction method (3), used as described above for the cholesterol oxidase experiment. The two methods gave virtually identical results. In some experiments, 10 l of each cell lysate were subjected to fractionation by SDS-10% polyacrylamide gel electrophoresis and analyzed by immunoblotting with an antibody to SR-BI (14) to qualitatively compare the levels of receptor expression from different cell clones. 3 H]cholesterol efflux assay. On day 4, the cells were washed once with medium A, and total cellular lipid was extracted two times with 1 ml of hexane/isopropyl alcohol (3:2; 10 min/extraction). The two extracts from each sample were pooled, dried, and resuspended in 150 l of isopropyl alcohol. The total radioactivity in each sample was determined by LSC of 10-l aliquots. The extent of [ 3 H]cholesteryl ester formation was determined by thin-layer chromatographic analysis of another 10-l aliquot as described above. The cellular material not extracted by the organic solvent was solubilized from the culture wells with 1 ml of 0.1 N NaOH, and the protein content was measured by the method of Lowry et al. (32) .
Immunoblotting and Immunofluorescence Microscopy-For immunoblotting, ldlA-7 and ldlA[mSR-BI] cells were plated in 6-well dishes, labeled with [ 3 H]cholesterol, and incubated in efflux medium in the presence or absence of KKB-1 antiserum and 50 g of protein/ml HDL for 2 h at 37°C as described above for the efflux assay. The efflux medium was removed, and the cells were rapidly washed two or three times with ice-cold PBS. The cells were then incubated in 200 l of lysis buffer for 30 min on ice. The lysate was clarified by centrifugation in a microcentrifuge for 2 min at 4°C. Supernatants (10 l/sample) were then fractionated by SDS-10% polyacrylamide gel electrophoresis and analyzed by immunoblotting using either a polyclonal antibody that recognizes the C-terminal cytoplasmic domain of SR-BI (antibody 495, Ref. 14, 33) or a mouse anti-human apoA-I antibody (19) . For immunofluorescence microscopy, the cells were set onto 12 ϫ 12-mm glass coverslips in 6-well dishes on day 0 in medium F. On day 2, cells were washed once with medium A and treated with medium A containing no additions or anti-mSR-BI KKB-1 antiserum (1:1000 dilution) for 45 min at 37°C. Cells were then washed twice with ice-cold PBS and fixed in PBS containing 2.5% paraformaldehyde for 30 min at room temperature. After washing four times with PBS, cells were processed for immunofluorescence microscopy as described previously (33) using KKB-1 antiserum (1:1000 dilution) as the first antibody and fluorescein isothiocyanate-labeled goat anti-rabbit IgG (1:1000 dilution) as the secondary antibody.
Isolation of Mutant M158R-We have previously described the retrovirus library-based activity dissection method for the isolation of mutant forms of SR-BI that exhibit novel phenotypes (28) . We used the same approach to isolate the M158R mutation used for this study. In brief, the cDNA encoding wild-type mSR-BI was cloned into the viral expression vector pMX to generate the vector pMX-mSR-BI (28) . The portion of the 5Ј-region of mSR-BI cDNA (from the 5Ј-end to the first NcoI site) encoding the N-terminal 165 residues of the protein was replaced with a collection of the corresponding mutated fragments generated by error-prone polymerase chain reaction (for details, see Ref. 28 ) to generate a library of mSR-BI mutants in the pMX vector (Sub1 library). This plasmid library was then converted into a retrovirus library by transfection into the Phoenix packaging cell line. Retroviruses harvested from the medium of the Phoenix cells were used to infect CHO[Eco] cells at low multiplicity of infection to generate a large number of stably transduced cell lines. This population of cells was then sequentially labeled with DiI-labeled HDL and Alexa-labeled HDL. Four sequential rounds of fluorescence-activated cell sorting were used to select a subpopulation of transduced cells that showed a DiI-negative, Alexa-positive phenotype. Genomic DNA was isolated from this population, and a collection of mutant mSR-BI cDNAs was isolated from the genomic DNA by high fidelity polymerase chain reaction and cloned into the pcDNA1 expression vector. The phenotypes of individual mutants were analyzed by transient transfection into COS M6 cells, and the sequences of some of the DiI-negative, Alexa-positive mutants were determined. Met-to-Arg or Met-to-Lys mutations at position 158 were identified in several clones along with mutations at other nonconserved sites. The M158R mutation was introduced into an otherwise wild-type mSR-BI cDNA in the pcDNA1 expression vector (28) to generate plasmid pcM158R. ldlA-7 cells stably transfected with this plasmid were then generated (see above).
Fluorescence Flow Cytometric Analysis of DiI Uptake from DiIlabeled HDL, DiI-labeled LDL, and DiI-labeled AcLDL-ldlA-7, ldlA[mSR-BI], ldlA[Q402R/Q418R], and ldlA[M158R] cells were plated at 250,000 cells/well in 6-well dishes in medium B on day 0. On day 2, the cells were washed once with PBS, and 1 ml of medium C containing 10 g of protein/ml DiI-labeled HDL, DiI-labeled LDL, or DiI-labeled AcLDL was then added to each well. After incubation at 37°C for 2 h, the cells were washed twice with PBS and harvested with 400 l of trypsin/EDTA (JRH Biosciences). The harvesting medium was then placed into plastic tubes (Falcon 2054) containing 1 ml of medium C. The amounts of DiI uptake were determined using a FACScan fluorescence flow cytometer (Becton Dickinson) as described previously (24 (Fig. 1B) . When labeled in NCLPDS-containing medium, both ldlA-7 and ldlA[mSR-BI] cells had more [ 3 H]cholesterol than when they were labeled in FBS-containing medium. However, there was only a slightly greater extent of labeling of the ldlA[mSR-BI] cells compared with the ldlA-7 cells under this condition (Fig. 1A) .
Most of the [ 3 H]cholesterol taken up by the cells remained as free cholesterol at the end of the equilibration step under both labeling conditions. When labeled in FBS-containing medium, ϳ11 and 1% of [ 3 H]cholesterol were converted into cholesterol ester in ldlA[mSR-BI] and ldlA-7 cells, respectively (Fig. 1D ). When labeled with the NCLPDS-containing medium, only 3.6 and 0.7% of total cellular [ 3 H]cholesterol were converted to cholesteryl ester in ldlA(mSR-BI) and ldlA-7 cells, respectively (Fig. 1C) . We thus chose to use NCLPDS-containing medium for [ 3 H]cholesterol labeling of ldlA-7 and ldlA-7 cells expressing wild-type and mutant mSR-BIs in most of the experiments described below.
Characterization of Anti-mSR-BI Antibody KKB-1-To generate a polyclonal anti-SR-BI antibody that could block the binding of ligands to SR-BI, we injected rabbits with an adenovirus encoding mSR-BI. Antiserum, designated KKB-1, was collected 6 or more weeks after injection. We then determined the effects of KKB-1 (1:1000 dilution) on the association of 125 I-HDL and 125 I-LDL with ldlA[mSR-BI] and ldlA-7 cells. The ldlA-7 cells are LDL receptor-negative mutants derived from Chinese hamster ovary cells (31) . They express a very low level of endogenous hamster SR-BI (14) . ldlA[mSR-BI] cells are transfected ldlA-7 cells that stably express a high level of mSR-BI (14) . Fig. 2A shows that KKB-1 antiserum and purified KKB-1 IgG reduced 125 I-HDL association with ldlA[mSR-BI] cells to levels slightly lower than those seen with control ldlA-7 cells (Fig. 2B) , whereas nonimmune ("control") serum or IgG had no effect. KKB-1 antiserum and IgG, but not the nonimmune controls, slightly reduced the initially low association of 125 I-HDL with the ldlA-7 cells (Fig. 2B) . This was presumably due to the low levels of endogenous SR-BI in these cells. Similar results were observed for the cell association of 125 I-LDL 
We also found that KKB-1 blocked SR-BI-mediated DiI uptake from DiI-labeled HDL into SR-BI-expressing cells (data not shown).
The inhibition of SR-BI activity by KKB-1 could have been direct (e.g. steric interference with ligand binding) or indirect (e.g. antibody-mediated reduction in the cellular levels of receptor and/or receptor redistribution from the surface to intracellular compartments). 3) ) with 50 g of protein/ml HDL in the absence (lanes 1 and 2) or presence (lane 3) of KKB-1 under conditions identical to those of the efflux experiments presented below. The cell lysates were then subjected to immunoblot analysis with either a second anti-mSR-BI antibody (antibody 495) (upper blot) or an antiapoA-I antibody that detects cell-associated HDL (lower blot). Incubation with the KKB-1 antibody blocked SR-BI-dependent association of HDL with the ldlA[mSR-BI] cells (loss of antiapoA-I signal) (lower blot, compare lanes 2 and 3), but did not alter the steady-state levels of total SR-BI protein (upper blot). Thus, KKB-1 did not inhibit HDL binding by reducing total cellular mSR-BI levels. In a similar experiment (Fig. 3B ), cells were preincubated without (panels 1Ј and 2Ј) or with (panel 3Ј) KKB-1 as described above, fixed (but left unpermeabilized), reincubated with KKB-1 and fluorescent secondary antibody, and subjected to immunofluorescence microscopy to visualize mSR-BI expressed on the cell surfaces. There was no apparent KKB-1-induced change in the level of surface expression (intensity of fluorescence estimated visually) or distribution of cell-surface mSR-BI. Thus, it is likely that the KKB-1 antibody directly blocked lipoprotein binding and consequent lipid uptake because its interaction with the receptor sterically interfered with ligand binding and binding-dependent activities such as selective lipid uptake. (Fig. 4B) , whereas it had little effect on efflux in the absence of the lipoprotein acceptor (Fig.  4A) . Addition of the KKB-1 antibody inhibited most of the SR-BI-dependent [ 3 H]cholesterol efflux (Fig. 4 , compare D and B), whereas the control nonimmune serum had virtually no effect on efflux (Fig. 4C) .
KKB-1 inhibition of [ 3 H]cholesterol efflux might have been due to the blocking of HDL binding, the alteration of lipid organization, or both. Therefore, we followed the approach used by Kellner-Weibel et al. (22) and measured the accessibility of cellular cholesterol to oxidation by cholesterol oxidase. Cells were labeled with [ 3 H]cholesterol; incubated in the presence or absence of the KKB-1 antibody; and then, without fixation, incubated with cholesterol oxidase. We then determined the percent of cellular [ 3 H]cholesterol converted to [ 3 H]cholestenone by the enzyme. For this experiment, cells were incubated in FBS-containing medium so that the conditions would be similar to those previously reported (22) . The results for cells incubated without the antibody or with nonimmune serum (Fig. 5, A and B) were similar to those reported by KellnerWeibel et al. (22) . We observed a significant SR-BI-dependent increase in (Fig. 5C) . These results raise the possibility that KKB-1 might have had some relatively minor direct effect on the lipid organization of the cells or perhaps might have interfered to some extent with the ability of the cholesterol oxidase to access surface cholesterol. In this regard, it is noteworthy that SR-BI clusters in caveolae in transfected cultured cells (33) , and it has been suggested that a significant fraction of the cholesterol oxidase-sensitive cholesterol might reside in caveolae (34) . The KKB-1 antibody bound to SR-BI in caveolae may have sterically interfered with the ability of cholesterol oxidase to modify caveolar cholesterol. It is possible that KKB-1 might alter some features of cell-surface lipid organization, i.e. the accessibility of cholesterol for dissociation from the cells, in a fashion not readily detected by the cholesterol oxidase assay. Nevertheless, the relatively small effects of KKB-1 on the cholesterol oxidase assay in COS cells (Fig. 5) relative to its dramatic inhibition of SR-BI-mediated efflux (Fig. 4) (31) . They are useful for studying the effects of LDL on cellular cholesterol metabolism mediated by transfected receptors without the potential confounding influence of endogenous LDL receptors (35) . Cells were labeled in NCLPDS-containing medium, which gives a comparable level of labeling for ldlA-7 and ldlA[mSR-BI] cells and a lower level of cholesteryl ester formation than labeling in FBS-containing medium (Fig. 1). Fig. 6 shows the kinetics of [ 3 H]cholesterol efflux from ldlA-7 and ldlA[mSR-BI] cells. As described previously in similar experiments by others (18), we observed essentially no efflux from either ldlA-7 or ldlA[mSR-BI] cells to the medium in the absence of an extracellular acceptor, i.e. lipoprotein (data not shown). We also confirmed previous reports (18, 20) that high expression of mSR-BI (ldlA[mSR-BI] cells) (Fig. 6 , A and C, q and E) significantly increased the rate of HDL (50 g of protein/ml; q and f)-and LDL (50 g of protein/ml; E and Ⅺ)-mediated efflux over that in the untransfected controls (f and Ⅺ). The SR-BI-enhanced [ 3 H]cholesterol efflux to both HDL and LDL was completely blocked by the KKB-1 antibody (Fig. 6, B and D) .
Furthermore, the antibody effectively inhibited SR-BI-enhanced [ 3 H]cholesterol efflux to both HDL and LDL during a 2-h incubation over a wide range of lipoprotein concentrations (20 -500 g of protein/ml) (Fig. 7, B and D; compare with efflux measured without the antibody in A and C). We routinely observed that the antibody could suppress some of the efflux from the untransfected control ldlA-7 cells. This is presumably a consequence of the contributions to background efflux by the low levels of endogenous hamster SR-BI expressed in the control ldlA-7 cells (Ref. 14; also see Ref. 18 ). 2 In contrast to the effects of the KKB-1 antibody, there was no effect on efflux to either HDL or LDL upon treatment of intact cells with a polyclonal antibody against the intracellular C-terminal cytoplasmic domain of SR-BI (14, 33) (data not shown). Thus, the effects of KKB-1 were not due to the nonspecific effects of addition of a rabbit polyclonal antibody. In addition, treatment with KKB-1 also abolished [ described SR-BI mutant that exhibits altered ligand binding properties (28) . This mutant has lost most of its ability to bind HDL, but not LDL (Ref. 28 and see below). The cDNA encoding this mutant was isolated from a randomly mutated library of mSR-BI cDNAs using the retrovirus library-based activity dissection method (28) . It has a double substitution of arginines for glutamines at positions 402 and 418 (Q402R/Q418R) in the extracellular domain of the molecule. This mutant SR-BI is as effective as wild-type mSR-BI in functioning as an LDL receptor, mediating high affinity LDL binding and uptake of metabolically active cholesterol from LDL; but it has lost most of the corresponding HDL receptor activity normally exhibited by the wild-type receptor (28) .
The abilities of cells expressing wild-type mSR-BI (ldlA[mSR-BI]) and the Q402R/Q418R mutant (ldlA[Q402R/ Q418R]) and untransfected control cells (ldlA-7) to mediate the cellular uptake of the lipophilic dye DiI from DiI-labeled HDL and DiI-labeled LDL are compared in Fig. 8 (A and B, respectively) . Previous studies have shown that the SR-BI-mediated transfer of DiI from DiI-labeled HDL to cells can be used as a reliable surrogate for the SR-BI-mediated selective uptake of cholesteryl esters from HDL (14, 36) . After incubation with DiI-labeled lipoproteins (10 g of protein/ml) for 2 h at 37°C, the cells were washed, and the uptake of DiI was quantified using fluorescence flow cytometry as described under "Experimental Procedures." The histograms in Fig. 8 (the intensity of the cellular DiI signal is shown on a log scale on the horizontal axes) show dramatically reduced DiI uptake from DiI-labeled HDL by ldlA[Q402R/Q418R] cells relative to ldlA[mSR-BI] cells (distribution shift to the left) (Fig. 8A) , whereas uptake of DiI from DiI-labeled LDL was not significantly reduced in the mutant (Fig. 8B) .
If the mechanism of SR-BI-mediated [ (Fig. 8, C and D, q and E) and mutant (OE and ‚) receptors were almost identical and were substantially higher than those from the ldlA-7 controls (Fig. 8D, f and  Ⅺ) . In contrast, the [ 3 H]cholesterol efflux rate to HDL from ldlA[Q402R/Q418R] cells was much lower (ϳ10 -20%) than that from ldlA[mSR-BI] cells and only slightly higher than that from the ldlA-7 controls (Fig. 8C) .
Several additional experiments were performed to determine if the differential effect of the Q402R/Q418R mutation on SR-BI-mediated [
3 H]cholesterol efflux to HDL and LDL was an artifact due to clonal variation in the stably transfected cells. We examined HDL-and LDL-dependent efflux from nine different Q402R/Q418R-expressing clones isolated by fluorescence-activated cell sorting and two different wild-type SR-BIexpressing isolates. There were varying levels of SR-BI or Q402R/Q418R protein expression (immunoblot analysis of some of the isolates) and varying levels of efflux activity in these isolates (data not shown). Nevertheless, the differential . The M158R mutant was identified using the retrovirus library-based activity dissection method (see "Experimental Procedures") and has a single amino acid substitution at position 158 (from Met to Arg) in the extracellular domain. This mutant is similar to the Q402R/Q418R mutant in that when it is expressed in transfected cells (ldlA[M158R]), it exhibits, relative to wild-type SR-BI, substantially reduced 125 I-HDL binding (data not shown) and reduced uptake of DiI from DiIlabeled HDL (Fig. 9A) . It differs from Q402R/Q418R in that its abilities to bind 125 I-LDL (data not shown) and to take up DiI from DiI-labeled LDL (Fig. 9B) are also reduced relative to wild-type mSR-BI. However, the M158R mutant retains nearly wild-type levels of DiI uptake from DiI-labeled AcLDL (Fig.  9C) . Thus, we conclude that the M158R mutation substantially reduced HDL and LDL (but not AcLDL) binding to the receptor. It is possible that the positively charged arginine side chain at position 158 of the mutant interfered with LDL binding by repelling one or more positively charged lysine side chains of apoB in native LDL and that neutralization of the charge(s) by acetylation permitted AcLDL binding. (Fig. 9F) . These results are consistent with the findings using the Q402R/Q418R mutant: when binding/lipid uptake was blocked, efflux was blocked. Taken together, all of the results involving a blocking antibody and two mutant forms of mSR-BI strongly suggest that SR-BI- Although the physiologic significance of SR-BI-mediated selective lipid uptake is now well established (15, 17, (37) (38) (39) , the physiologic relevance of SR-BI-mediated cholesterol efflux remains unclear. It has been suggested that the expression of SR-BI by macrophages in atherosclerotic plaque (18, 40) might contribute to cholesterol efflux and protect against atherosclerosis. We have compared cholesterol efflux from peritoneal macrophages isolated from wild-type control and SR-BI homozygous null mice (37) and observed no differences. 3 Thus, SR-BI is not required for cholesterol efflux from peritoneal macrophages as measured by standard cell culture techniques. (It is important to note that in our hands, the cultured macrophages from wild-type mice expressed very low levels of SR-BI. Thus, this experiment established that SR-BI is not necessary for cholesterol efflux from macrophages, but did not determine if SR-BI can contribute to efflux when it is expressed at higher levels by macrophages.) SR-BI is unlikely to play an essential role in cholesterol efflux to nascent HDL particles (e.g. pre-␤-HDL) in vivo. Lipidfree apoA-I and lipid-poor pre-␤ 1 -HDL are poor ligands for SR-BI relative to lipid-rich spherical ␣-HDL particles (19) , and it has been reported that SR-BI does not enhance cholesterol efflux to lipid-free apoA-I (18, 21) . Furthermore, the effects of a null mutation in SR-BI on plasma HDL cholesterol are dramatically different than those of a null mutation in the Tangier disease gene ABC1. The ABC1 gene plays a critical role in apoA-I-dependent cholesterol and phospholipid efflux from cells (6, 13) . Although both human and murine ABC1 deficiencies result in an almost complete absence of plasma HDL cholesterol, especially in cholesterol-rich spherical ␣-HDL particles (6 -13) , there is a doubling of plasma HDL cholesterol in SR-BI homozygous null knockout mice (37 than nascent HDL. SR-BI has also been shown to be expressed on the apical surface of enterocytes in the intestine (41) and on the canalicular surface of hepatocytes in mice overexpressing SR-BI in the liver (17) . Thus, SR-BI-mediated efflux has the potential of contributing to cholesterol secretion from the body. Additional experiments will be required to determine if there are circumstances under which SR-BI-mediated cholesterol efflux is physiologically relevant.
Regardless of its physiologic significance, SR-BI-mediated cholesterol efflux provides an important tool for examining the detailed molecular mechanisms by which this receptor influences cellular cholesterol metabolism. The mechanisms underlying SR-BI-mediated selective lipid uptake and cholesterol efflux are not well defined. It has been proposed that SR-BI may form a lipid channel, which facilitates transfer of lipid between cells and lipoproteins (42, 43) . Alternatively, SR-BI might facilitate hemifusion (44, 45) between the lipid monolayer shells of spherical lipoproteins and the external monolayer of the plasma membrane. In the hemifused state, cholesteryl esters from the core of the lipoprotein would be in direct contact with the hydrophobic center of the membrane, from which they could then be transported to other cellular compartments. In addition, unesterified cholesterol would be expected to readily exchange between the outer shell phospholipid monolayer of the lipoprotein and the external monolayer of the plasma membrane to which it was fused. This might contribute to lipoprotein/SR-BI-mediated [ 3 H]cholesterol efflux, which would occur after fission of these monolayers on release of the cholesteryl ester-depleted lipoprotein from the cell surface. Thus, a hemifusion mechanism could account for the correlation of SR-BI-mediated selective uptake and efflux/ exchange activities that we report here. However, marked differences in the rates of selective uptake of different phospholipid classes have been reported and suggested to raise doubts about hemifusion mechanisms (42) . Future experiments involving reconstitution of purified components (SR-BI, membrane lipids) into a functioning in vitro system should help in the exploration of the mechanisms underlying these SR-BI activities.
